Pfizer’s Ibrance breast-cancer drug succeeds in getting preliminary approval
Pfizer Inc. (NYSE:PFE) - A late-stage study and trial of Ibrance breast-cancer drug was delayed by Pfizer as a result of efficacy issues. The halting of the study was tagged to an assessment by an independent d...